Neurology’s human data revolution

Outside of oncology, nowhere is the confluence of genetic insights and new preclinical tools yielding greater leaps than in neurology. Despite the many kinks still to iron out, investors and pharmas now have a lot more to work with in defining criteria to pursue new targets for neurological diseases.

In both neurodegeneration and neuropsychiatry, the human-first approach, the availability of data on genetic linkage to disease and the ability to interrogate mechanisms in new disease-relevant ways are allowing researchers to make the case for causality...